{"id":8850,"date":"2020-08-12T21:19:05","date_gmt":"2020-08-13T02:19:05","guid":{"rendered":"https:\/\/saluddigital.com\/?p=8850"},"modified":"2025-10-21T14:35:38","modified_gmt":"2025-10-21T20:35:38","slug":"astrazeneca-anuncia-acuerdo-con-la-fundacion-carlos-slim-para-suministrar-la-vacuna-covid-19-a-america-latina","status":"publish","type":"post","link":"https:\/\/saluddigital.com\/en\/noticias\/astrazeneca-anuncia-acuerdo-con-la-fundacion-carlos-slim-para-suministrar-la-vacuna-covid-19-a-america-latina\/","title":{"rendered":"AstraZeneca announces agreement with the Carlos Slim Foundation to supply the COVID-19 vaccine to Latin America"},"content":{"rendered":"
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

(<\/strong>Mexico, August 12, 2020) \u2013<\/strong>\u00a0AstraZeneca signed an agreement with the Carlos Slim Foundation, a Mexican non-profit organization, to contribute to the production in Argentina and Mexico and distribution without economic benefit in Latin America, of the potential COVID-19 vaccine, AZD1222, during the pandemic. This agreement will initially provide 150 million doses in the region, excluding Brazil, which will be covered by AstraZeneca's agreement with the Brazilian Government announced last June. Shipments are expected to begin in the first half of 2021, should clinical trials prove successful.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

AstraZeneca recognizes the urgency of the global pandemic and will work in partnership with partners to supply the vaccine so that it is equitably available. AstraZeneca is working with strategic partners in Latin America, including Argentina and Mexico, taking advantage of their production capacity to facilitate the early availability of the potential vaccine.<\/p>\n

\u00a0<\/p>\n

This is another important milestone in AstraZeneca's response to the COVID-19 pandemic and in its efforts to support broad and equitable access to the potential vaccine. Recently, the University of Oxford and AstraZeneca announced interim results from a UK phase I\/II clinical trial that showed robust immune responses against the SARS-CoV2 virus in all participants.<\/p>\n

\u00a0<\/p>\n

Sylvia Varela<\/strong>, President and CEO of AstraZeneca, Mexico, said: \u201cWe are very proud of the work that AstraZeneca does on the science front and within the industry to help save lives and mitigate devastating humanitarian consequences, social and economic that this global pandemic has had. And, in particular, it fills us with great satisfaction to be part of an alliance with partners in Latin America where our sole objective is to provide rapid access to the potential vaccine in Mexico and throughout the Latin American region."<\/p>\n

\u00a0<\/p>\n

The Carlos Slim Foundation<\/strong>, expressed: \u201cWe are concerned about collaborating in combating this unprecedented pandemic that has a great impact on health, the economy and employment, with consequences for people and their families. We regret the loss of numerous lives, as well as the impact on the global economy and employment. Based on the research of the University of Oxford and AstraZeneca, a potential vaccine is in development that is in phase 3 with encouraging expectations, consequently we join the effort for its production in Mexico and Argentina so that the supply to Latin America. If its efficacy and safety are proven and it is approved by the health authorities, it would make a decisive contribution to avoiding further loss of life, and would allow a return to normality.\u201d<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

ABOUT ASTRAZENECA<\/strong><\/p>\n

\u00a0<\/p>\n

AstraZeneca is a science-led global biopharmaceutical company focused on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas: oncology, cardiovascular, renal and metabolism, and respiratory and immunology. Headquartered in Cambridge, UK, AstraZeneca operates in more than 100 countries and its innovative medicines are used by millions of patients around the world. Visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

(M\u00e9xico, 12 de Agosto de 2020) \u2013 AstraZeneca firm\u00f3 un acuerdo con la Fundaci\u00f3n Carlos Slim, organizaci\u00f3n mexicana sin fines de lucro, para contribuir a la producci\u00f3n en Argentina y M\u00e9xico y distribuci\u00f3n sin beneficio econ\u00f3mico en Am\u00e9rica Latina, de la potencial vacuna COVID-19, AZD1222, durante la pandemia. Este acuerdo proveer\u00e1 inicialmente 150 millones de dosis en la regi\u00f3n, excluyendo Brasil, que ser\u00e1 cubierto por el acuerdo de AstraZeneca con el Gobierno Brasile\u00f1o anunciado en junio pasado. Se espera iniciar los env\u00edos en el primer semestre de 2021, en caso de que los ensayos cl\u00ednicos resulten exitosos. AstraZeneca reconoce la urgencia de la pandemia mundial y trabajar\u00e1 en alianza con socios para el suministro de la vacuna de forma que est\u00e9 disponible de manera equitativa. AstraZeneca se encuentra trabajando con socios estrat\u00e9gicos en Latinoam\u00e9rica, incluyendo Argentina y M\u00e9xico, aprovechando su capacidad productiva para facilitar la disponibilidad temprana de la potencial vacuna. Este es otro hito importante en la respuesta de AstraZeneca a la pandemia de COVID-19 y en sus esfuerzos para apoyar un acceso amplio y equitativo a la potencial vacuna. Recientemente, la Universidad de Oxford y AstraZeneca anunciaron resultados provisionales de un ensayo cl\u00ednico de fase I \/ II en el Reino Unido que mostr\u00f3 respuestas inmunes s\u00f3lidas contra el virus SARS-CoV2 en todos los participantes. Sylvia Varela, Presidente y Directora General de AstraZeneca, M\u00e9xico, se\u00f1al\u00f3: \u201cPara nosotros, es un motivo de gran orgullo el trabajo que realiza AstraZeneca en el frente de la ciencia y dentro de la industria para contribuir a salvar vidas y mitigar las consecuencias devastadoras humanitarias, sociales y econ\u00f3micas que ha tenido esta pandemia global. Y, en particular, nos llena de enorme satisfacci\u00f3n ser parte de una alianza con socios de Am\u00e9rica Latina donde nuestro \u00fanico objetivo es proveer un acceso r\u00e1pido a la potencial vacuna en M\u00e9xico y en toda la regi\u00f3n de Am\u00e9rica Latina\u201d. La Fundaci\u00f3n Carlos Slim, expres\u00f3: \u201cEstamos preocupados por colaborar en combatir esta in\u00e9dita pandemia que tiene gran impacto en la salud, la econom\u00eda y el empleo, con consecuencias en las personas y sus familias. Lamentamos la p\u00e9rdida de numerosas vidas, as\u00ed como la afectaci\u00f3n de la econom\u00eda y el empleo global. En base a las investigaciones de la Universidad de Oxford y AstraZeneca est\u00e1 en desarrollo una potencial vacuna que se encuentra en fase 3 con expectativas alentadoras, consecuentemente nos sumamos al esfuerzo para su producci\u00f3n en M\u00e9xico y Argentina con el fin de que se inicie el suministro a Am\u00e9rica Latina.  En caso de que se demuestre su eficacia y seguridad y sea aprobada por las autoridades sanitarias, contribuir\u00eda de forma determinante a evitar m\u00e1s p\u00e9rdidas de vidas, y permitir\u00eda el regreso a la normalidad\u201d. ACERCA DE ASTRAZENECA AstraZeneca es una compa\u00f1\u00eda biofarmac\u00e9utica global liderada por la ciencia que se enfoca en el descubrimiento, desarrollo y comercializaci\u00f3n de medicamentos recetados, principalmente para el tratamiento de enfermedades en tres \u00e1reas de terapia: oncolog\u00eda, cardiovascular, renal y metabolismo, y respiratorio e inmunolog\u00eda. Con sede en Cambridge, Reino Unido, AstraZeneca opera en m\u00e1s de 100 pa\u00edses y sus medicamentos innovadores son utilizados por millones de pacientes en todo el mundo. Visite astrazeneca.com y siga a la Compa\u00f1\u00eda en Twitter @AstraZeneca.<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[160],"tags":[],"class_list":["post-8850","post","type-post","status-publish","format-standard","hentry","category-noticias"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/posts\/8850","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/comments?post=8850"}],"version-history":[{"count":0,"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/posts\/8850\/revisions"}],"wp:attachment":[{"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/media?parent=8850"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/categories?post=8850"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/tags?post=8850"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}